Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Yourgene Health (LON: YGEN) announced on Friday that it has been awarded a contract to supply its Elucigene DPYD testing kits to NHS Wales.
The Elucigene DPYD screens cancer patients before the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects.
The two-year contract is due to begin in July and is worth approximately £232,000. There is an initial period of 12 months with an option to extend for a further 12 months.
Lyn Rees, CEO of Yourgene Health, commented: “We are extremely pleased to be awarded this tender to supply our IVD-marked oncology product to NHS Wales, with our differentiated technology deemed the only technology suitable for meeting the lab requirements to deliver the service.
“We are proud to see this form of personalised medicine increasing in demand and routinely being used across Wales.”
Yourgene Health's share price is currently down 2.05% at 12.94p.
Yourgene Health shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Yourgene Health shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .